MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
03 nov. 2022 16h01 HE | MacroGenics, Inc.
Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-endAnticipated update...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
02 nov. 2022 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
26 oct. 2022 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
02 sept. 2022 07h00 HE | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
08 août 2022 16h01 HE | MacroGenics, Inc.
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
25 juil. 2022 16h01 HE | MacroGenics, Inc.
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
08 juil. 2022 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
08 juin 2022 16h01 HE | MacroGenics, Inc.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Appointment of William Heiden to Board of Directors
23 mai 2022 16h01 HE | MacroGenics, Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
17 mai 2022 16h01 HE | MacroGenics, Inc.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...